Dr. Comer received a B.A. in Chemistry from Carleton College in 1957, and a Ph.D. in Organic Chemistry, Pharmacology from the University of Iowa in 1961. From 1961-1991 he was employed by Mead Johnson & Co. which was acquired by Bristol-Myers; he was responsible for discovery and worldwide clinical development of pharmacodynamic agents and was President of Pharmaceutical Research and Licensing until the merger in 1990 to become Bristol-Myers Squibb, when he became Senior Vice President of Strategic Management. He managed the discovery and development of more than 10 blockbuster products. From April 1991 until November 1999 he was President and CEO of SIBIA Neurosciences, a company focusing on drug discovery and the development of neurodegenerative disease therapeutics, which became publicly traded in May 1996 and was acquired by Merck in November 1999.
Currently, Dr. Comer is the Founder, President and CEO of NeuroGenetic Pharmaceuticals, Inc.
At the time of this interview Dr. Comer served as the Founder, President and CEO of NeuroGenetic Pharmaceuticals, Inc.